Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.36
(2.86%)
HKD 0.36
(2.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 709.65 Million HKD | -78.66% |
| 2022 | 3.32 Billion HKD | -8.57% |
| 2021 | 3.63 Billion HKD | -9.39% |
| 2020 | 4.01 Billion HKD | 7.42% |
| 2019 | 3.73 Billion HKD | 271.24% |
| 2018 | 1 Billion HKD | -8.2% |
| 2017 | 1.09 Billion HKD | 19.76% |
| 2016 | 915.52 Million HKD | 0.84% |
| 2015 | 907.89 Million HKD | 16.7% |
| 2014 | 777.94 Million HKD | 53.13% |
| 2013 | 508.04 Million HKD | 38.31% |
| 2012 | 367.33 Million HKD | 41.96% |
| 2011 | 258.76 Million HKD | 21.44% |
| 2010 | 213.07 Million HKD | 61.63% |
| 2009 | 131.83 Million HKD | -14.16% |
| 2008 | 153.57 Million HKD | -50.22% |
| 2007 | 308.47 Million HKD | 128.14% |
| 2006 | 135.21 Million HKD | -28.53% |
| 2005 | 189.19 Million HKD | -17.28% |
| 2004 | 228.72 Million HKD | 98.12% |
| 2003 | 115.45 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 3.09 Billion HKD | 0.0% |
| 2023 FY | 709.65 Million HKD | -78.66% |
| 2023 Q4 | 709.65 Million HKD | 0.0% |
| 2022 Q2 | 3.38 Billion HKD | 0.0% |
| 2022 FY | 3.32 Billion HKD | -8.57% |
| 2022 Q4 | 3.32 Billion HKD | 0.0% |
| 2021 Q4 | 3.63 Billion HKD | 0.0% |
| 2021 Q2 | 3.99 Billion HKD | 0.0% |
| 2021 FY | 3.63 Billion HKD | -9.39% |
| 2020 Q4 | 4.01 Billion HKD | 0.0% |
| 2020 FY | 4.01 Billion HKD | 7.42% |
| 2020 Q2 | 4.62 Billion HKD | 0.0% |
| 2019 FY | 3.73 Billion HKD | 271.24% |
| 2019 Q2 | 1.19 Billion HKD | 0.0% |
| 2019 Q4 | 4.37 Billion HKD | 0.0% |
| 2018 Q4 | 1 Billion HKD | 0.0% |
| 2018 Q2 | 1.09 Billion HKD | 0.0% |
| 2018 FY | 1 Billion HKD | -8.2% |
| 2017 FY | 1.09 Billion HKD | 19.76% |
| 2017 Q2 | 898.53 Million HKD | 0.0% |
| 2017 Q4 | 1.09 Billion HKD | 0.0% |
| 2016 Q4 | 915.52 Million HKD | 0.0% |
| 2016 Q2 | 922.38 Million HKD | 0.0% |
| 2016 FY | 915.52 Million HKD | 0.84% |
| 2015 Q4 | 907.89 Million HKD | 0.0% |
| 2015 Q2 | 724.29 Million HKD | 0.0% |
| 2015 FY | 907.89 Million HKD | 16.7% |
| 2014 Q3 | 777.94 Million HKD | 34.65% |
| 2014 FY | 777.94 Million HKD | 53.13% |
| 2014 Q1 | 577.76 Million HKD | 13.72% |
| 2014 Q4 | 777.94 Million HKD | 0.0% |
| 2014 Q2 | 577.76 Million HKD | 0.0% |
| 2013 Q1 | 465.85 Million HKD | 26.82% |
| 2013 Q4 | 508.04 Million HKD | 0.0% |
| 2013 FY | 508.04 Million HKD | 38.31% |
| 2013 Q3 | 508.04 Million HKD | 9.06% |
| 2013 Q2 | 465.85 Million HKD | 0.0% |
| 2012 Q1 | 259.92 Million HKD | 0.45% |
| 2012 Q4 | 367.33 Million HKD | 0.0% |
| 2012 Q3 | 367.33 Million HKD | 41.33% |
| 2012 FY | 367.33 Million HKD | 41.96% |
| 2012 Q2 | 259.92 Million HKD | 0.0% |
| 2011 Q4 | 258.76 Million HKD | 0.0% |
| 2011 FY | 258.76 Million HKD | 21.44% |
| 2011 Q2 | 266.43 Million HKD | 0.0% |
| 2010 FY | 213.07 Million HKD | 61.63% |
| 2010 Q2 | 137.67 Million HKD | 0.0% |
| 2010 Q4 | 213.07 Million HKD | 0.0% |
| 2009 Q4 | 131.83 Million HKD | 0.0% |
| 2009 FY | 131.83 Million HKD | -14.16% |
| 2008 FY | 153.57 Million HKD | -50.22% |
| 2007 FY | 308.47 Million HKD | 128.14% |
| 2006 FY | 135.21 Million HKD | -28.53% |
| 2005 FY | 189.19 Million HKD | -17.28% |
| 2004 FY | 228.72 Million HKD | 98.12% |
| 2003 FY | 115.45 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -398.766% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 90.205% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -316.447% |
| Qianhai Health Holdings Limited | 94 Million HKD | -654.927% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 23.699% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 21.479% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -6.652% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -2.9% |
| SSY Group Limited | 4.49 Billion HKD | 84.209% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -93.496% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 34.924% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.579% |